Andere Sprachen Ribomic Inc.

Aktien

A12ENT

JP3974850004

4591

Verzögert Japan Exchange Andere Börsenplätze 08:00:00 06.06.2024			% 5 Tage	% 1. Jan.
87 ^JPY	-3,33 %		+1,16 %	-19,44 %

13.02.	Ribomic Inc. meldet Ergebnis für die neun Monate bis zum 31. Dezember 2023	CI
17.01.	Ribomic geht Zusammenarbeit mit Ajinomoto in der Arzneimittelforschung ein	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	07.03.
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	20.02.
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	13.02.
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	17.01.
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	17.01.
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	16.01.
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	05.12.
RIBOMIC Phase I and II Data Published in the Eye	05.12.
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13.11.
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	10.08.23
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	10.08.23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12.05.23
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	12.05.23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12.05.23
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	28.04.23
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	10.02.23
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	10.02.23
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	27.12.22
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	23.12.22
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two	29.11.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ribomic Inc.

Aktien

A12ENT

JP3974850004

4591

Andere Sprachen

Filter